New real-world data from Oregon indicate that state-regulated psilocybin therapy is associated with meaningful improvements in mood disorders, including symptoms of depression, anxiety and post-traumatic stress disorder, according to a study published Aug. 19 in JAMA Network Open.
Study of licensed services
Researchers led by Oregon Health & Science University evaluated nearly 350 people who received psilocybin at 24 of Oregon’s 26 licensed service centers. All participants underwent a single psilocybin session between November 2024 and June 2026 under the supervision of a licensed facilitator.
One month after treatment, study participants reported high perceived benefit: nearly 92% said they had benefitted from the experience and 65% ranked it among the 10 most meaningful events of their lives. At three months, measures showed reduced symptoms of depression, anxiety and PTSD and improvements in overall well-being and life satisfaction.
Implications and cautions
OHSU, which led the evaluation of Oregon’s psilocybin program, framed the findings as early evidence that legalized psilocybin services may improve health outcomes for people accessing these treatments in an organized, state-regulated system.
“These early results reveal psilocybin’s potential to improve health in people accessing these services here in Oregon,”
The university’s president, Dr. Shereef Elnahal, said the data also provide insights for policymakers evaluating programs that permit psychedelic therapies for mental health conditions, including PTSD and substance use disorders that affect U.S. military veterans. Elnahal, identified in the study background as a former undersecretary for health at the U.S. Department of Veterans Affairs, was not involved in the research.
Although the findings were largely positive, they were not without concerns. A small number of participants experienced behavioral reactions to the drug that required medical attention; the report said four people needed such care. No serious adverse events were reported in the study.
Context: Oregon’s experiment with regulated access
Voters in Oregon approved a measure in 2020 that paved the way for state-licensed psilocybin services. Legal access for adults 21 and older began in 2023, and more than 20,000 people have used Oregon-licensed psilocybin services through the period covered by the evaluation.
The study represents one of the first large-scale assessments of outcomes from a legalized, regulated market for a psychedelic compound in the United States. Researchers collected outcomes from patients receiving care in routine service settings rather than within a controlled clinical-trial framework, making the data reflective of real-world practice in Oregon’s program.
- Participants evaluated: ~350 people across 24 centers
- Timing of sessions: November 2024–June 2026
- Reported benefit at one month: 92%
- Ranked among most meaningful life events: 65%
- Medical attention required: 4 participants (behavioral reactions)
Researchers measured multiple outcome domains and reported improvements at three months in symptoms related to mood and traumatic stress, alongside gains in life satisfaction and general well-being.
What this means for policy and further research
Advocates and some policymakers have pointed to Oregon’s program as a model for how psychedelic-assisted therapies might be incorporated into mental health care under state regulation. The results add to a growing body of evidence from clinical trials and observational studies suggesting therapeutic potential for psilocybin in mood and trauma-related disorders.
At the same time, the study underscores the need for continued monitoring of safety in real-world settings and for additional research to define best practices for screening, facilitation, dosing and follow-up care. The evaluation does not replace randomized controlled trials but provides data relevant to states and institutions considering regulated access programs.
For clinicians, policymakers and patients, the Oregon experience will likely inform debates about the role of psychedelics in mental health treatment and whether similar regulatory frameworks should be adopted elsewhere in the United States.
